Jardiance Adolescent (12-17) School and Activity Considerations

Why FDA Approval in Adolescents Matters for School Planning

The FDA approved empagliflozin for patients aged 10 and older with type 2 diabetes in December 2023, based on the DINAMO trial, making it one of the first SGLT2 inhibitors with a pediatric label in that age range. [1] Before that approval, providers faced an off-label gap for this class; now schools and adolescent patients have a drug with dedicated safety data. Understanding that data is the starting point for any school-day or activity plan.

What DINAMO Showed About Young Patients

The DINAMO trial (NCT03429543) enrolled 157 pediatric patients aged 10 to 17 with type 2 diabetes. Empagliflozin 10 mg reduced HbA1c by a mean of 0.84% versus placebo at 26 weeks. [1] Adverse events specific to the pediatric cohort included genital mycotic infections and, importantly, volume depletion events. Those volume depletion events are the clinical underpinning for every hydration and exercise caution discussed in this article.

The SGLT2 Mechanism and Why It Creates School-Specific Problems

Empagliflozin inhibits sodium-glucose cotransporter 2 in the proximal tubule, blocking reabsorption of roughly 50 to 90 grams of glucose per day and excreting it in urine. [2] That osmotic effect pulls water into the tubular lumen, increasing urine volume by 200 to 400 mL per day above baseline in adults. Adolescents with lower body mass may see proportionally larger relative fluid shifts. More urine output means more bathroom trips and more insensible losses. In a 50-minute class, this is manageable with a bathroom pass. During a three-hour exam block or a 90-minute soccer match, it requires deliberate planning.

Setting Up the School Health Record

Every adolescent on empagliflozin should have an updated school health record and an individualized healthcare plan (IHP) before the first day of a new semester. The American Diabetes Association's 2024 Standards of Care recommend that diabetes management plans for youth address the school environment explicitly. [3]

What to Include in the IHP

The IHP should document four things for staff:

• Bathroom access: The student has a medical need for unrestricted bathroom access. Delaying urination increases UTI risk, and SGLT2 inhibitors already raise that baseline risk by 1.5-fold in some populations. [4]
• Water bottle policy: The student should carry a 500 to 750 mL water bottle and be permitted to drink during class.
• DKA recognition: School nurses need a written list of DKA warning signs specific to SGLT2 inhibitors. These include nausea, vomiting, abdominal pain, and rapid breathing. Blood glucose may appear only mildly elevated (euglycemic DKA), which is why the school nurse must not dismiss symptoms because a fingerstick reads 180 mg/dL. [5]
• Sick-day protocol: If the student vomits at school, the parent or guardian must be contacted immediately and empagliflozin should be withheld until a provider clears resumption.

Communicating with the School Nurse

A brief letter from the prescribing clinician, updated each academic year, is the single most effective intervention. The Endocrine Society's clinical practice guidelines on diabetes in youth note that healthcare team communication with school personnel substantially improves glycemic outcomes. [6] The letter should name the drug, the dose, the bathroom and hydration accommodations needed, and the DKA action plan.

Exercise, Sports, and Physical Education

Physical activity is strongly encouraged for adolescents with type 2 diabetes. The ADA 2024 Standards of Care recommend at least 60 minutes of moderate-to-vigorous physical activity daily for youth with diabetes. [3] Empagliflozin does not cause hypoglycemia when used as monotherapy, because it is glucose-dependent. That is a genuine safety advantage compared with sulfonylureas. The concern with exercise is fluid balance, not low blood sugar.

Hydration Strategy During Sport

During aerobic exercise, sweat losses in adolescents can reach 0.5 to 1.5 liters per hour depending on body size and ambient temperature. [7] Add the 200 to 400 mL extra daily urine output from empagliflozin and the cumulative deficit during a two-hour practice session could approach 2 liters in a larger teen. That level of dehydration causes measurable performance decline and, in extreme cases, may precipitate hemodynamic instability.

A practical framework:

• Drink 400 to 600 mL of water or electrolyte solution 30 minutes before practice.
• Drink 150 to 250 mL every 15 to 20 minutes during activity.
• Rehydrate with at least 500 mL after activity.

Sports drinks containing sodium (400 to 700 mg per liter) are preferred over plain water for sessions lasting more than 60 minutes, because SGLT2-related natriuresis mildly increases sodium losses. [8]

When to Hold Empagliflozin Before Activity

No guideline currently recommends routine pre-exercise drug holidays for SGLT2 inhibitors in type 2 diabetes outside of surgical or fasting contexts. [5] However, if an adolescent has signs of volume depletion (dizziness on standing, dark urine, dry mouth) before a match or game, the dose should be discussed with the prescribing clinician. Missing one morning dose is far safer than competing while dehydrated.

Contact Sports and Injury Risk

Empagliflozin does not impair wound healing at standard doses in the evidence base for adolescents, but the broader SGLT2 inhibitor literature has noted an association with lower limb complications in older adults with peripheral vascular disease. [9] In healthy adolescents with type 2 diabetes and no vascular comorbidities, contact sport participation is generally safe. Standard wound care after abrasions is sufficient.

Field Trips, Travel, and Overnight Activities

School trips add complexity because routines break down. Empagliflozin is a once-daily morning medication, so dose timing is relatively simple. The more pressing concern is access to fluids, bathrooms, and emergency support during unstructured time.

Packing and Storage

Empagliflozin tablets are stable at room temperature between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius). [10] They do not require refrigeration. A student can carry a week's supply in a standard daily pill organizer. The prescribing clinician should provide a letter for airport security or border crossings that identifies the medication by name and dose.

Sick-Day Rules on the Road

Vomiting or diarrhea during a trip is the highest-risk scenario. Both reduce fluid intake and increase fluid losses simultaneously. The FDA label for empagliflozin includes an explicit recommendation to hold the drug during periods of reduced oral intake or fluid losses. [10] The student's chaperone should have written instructions: if the teen vomits once, hold the next dose and call the parent or guardian. If vomiting is repeated or accompanied by abdominal pain, seek emergency care. This is not optional follow-up.

Insulin Users on SGLT2 Inhibitors

Some adolescents with type 2 diabetes also require insulin, particularly those with significant beta-cell dysfunction. In this subgroup, the DKA risk from SGLT2 inhibitors is higher because insulin suppresses ketogenesis. [5] Any teen on combined insulin plus empagliflozin therapy needs a clear euglycemic DKA protocol documented in the IHP and carried on trips.

Genital and Urinary Hygiene at School

Glucosuria creates a nutrient-rich environment for Candida species and bacteria. In the DINAMO trial, genital mycotic infections occurred in a small but real proportion of the pediatric cohort. [1] For adolescent girls in particular, this means daily perineal hygiene with water and a mild, unscented cleanser. Changing out of wet athletic clothing promptly after PE or sport is practical advice that coaches and PE teachers can reinforce without needing to know the medication.

UTI Recognition

Urinary tract infections are more frequent in patients on SGLT2 inhibitors. [4] Adolescents may minimize or dismiss symptoms like burning on urination or frequent urges to urinate because they already urinate frequently on the drug. They need to know: if urination becomes painful, if there is blood in the urine, or if fever develops alongside urinary symptoms, they should tell a parent or school nurse the same day. A 3 to 7-day course of an appropriate antibiotic resolves most uncomplicated UTIs if caught early. Untreated UTIs in a patient already taking an SGLT2 inhibitor can ascend to the kidney more quickly than in an untreated patient.

Monitoring and Dose Adjustments During the School Year

Routine monitoring keeps empagliflozin safe over the long school year. The ADA 2024 standards recommend HbA1c measurement every 3 months when the regimen is being optimized, and every 6 months once stable. [3] Renal function (serum creatinine, eGFR) should be checked at least annually; empagliflozin is not recommended if eGFR falls below 45 mL/min/1.73m² in pediatric patients. [10]

Signs That the Dose May Need Review

The prescribing clinician should be notified if the adolescent reports any of the following during the school year:

• Dizziness when standing up from a chair (orthostatic hypotension)
• Recurring genital itching or discharge despite hygiene measures
• Any episode of nausea or abdominal pain without a clear cause
• Significant weight loss beyond what is expected

Weight loss is a pharmacologic effect of SGLT2 inhibitors in adults, averaging 1.5 to 3 kg in trials. [11] In growing adolescents, unexpected weight loss or failure to gain weight at the expected rate warrants evaluation, because caloric loss through glucosuria may affect growth if caloric intake is not adjusted.

Exam Stress and Glycemic Variability

Cortisol release during academic stress raises blood glucose. Because empagliflozin's glucose-lowering is proportional to ambient glucose levels, higher stress-related glucose will increase urinary glucose excretion and therefore increase urinary volume during exam periods. A teen who normally manages on two bathroom trips per morning may need three during finals week. Acknowledging this and building it into the exam accommodation request prevents avoidable distress.

Talking to Coaches, Teachers, and Peers

Adolescents often resist disclosing medical information at school. Disclosure is the student's legal right to make in most circumstances, but there is a safety floor: at minimum, one designated adult at school (the nurse, a coach, a trusted teacher) should know the student is on a medication that requires hydration support and carries a DKA risk.

A study examining diabetes disclosure in adolescents found that peer knowledge of diabetes management was associated with better adherence and lower rates of school-day glycemic events. [12] The student does not need to announce their diagnosis. Having one informed adult present during sport or overnight trips is sufficient to cover the highest-risk scenarios.

Scripts for Common Situations

Coaches asking why the student is drinking constantly: "I take a medication that makes me urinate more, so I need to drink more." No diagnosis required.

Teachers questioning bathroom frequency: "I have a documented medical need for bathroom access. My school nurse has a copy of my healthcare plan." That sentence, delivered calmly, usually ends the exchange.

Special Situations: Ramadan, Fasting, and Religious Observance

Fasting during Ramadan or other religious observances requires specific planning for any patient on empagliflozin. Extended fasting reduces oral intake, and the FDA label identifies reduced oral intake as a reason to consider holding the drug. [10] The prescribing clinician should be consulted at least two weeks before a planned fast. Some endocrinologists recommend holding empagliflozin on full fast days and resuming on non-fast days; others adjust to a 10 mg dose regardless of the usual 25 mg titration. There is no single published consensus for adolescents specifically, but the general adult SGLT2 inhibitor Ramadan guidance from Hassanein et al. (2021) in Diabetes Research and Clinical Practice recommends pre-Ramadan structured education for all patients on this drug class. [13]

Key Numbers to Memorize

Empagliflozin 10 mg reduces HbA1c by approximately 0.84% at 26 weeks in adolescents per DINAMO. [1] Adults in EMPA-REG OUTCOME (N=7,020) showed a 14% relative reduction in cardiovascular death plus non-fatal MI plus non-fatal stroke at a median 3.1 years follow-up. [14] While cardiovascular outcome data in adolescents do not yet exist at the same scale, the mechanism is the same, and establishing good adherence habits during the teen years builds the foundation for long-term cardiovascular benefit as adults.

The FDA label requires eGFR of at least 45 mL/min/1.73m² for use in pediatric patients. [10] Blood pressure may fall 1 to 3 mmHg systolic due to volume effects; teens who are already lean should have blood pressure checked at each visit.